Clinicopathological characteristics and intrarenal angiotensin II expression in X-linked Alport syndrome

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• An update on the pathomechanisms and future therapies of Alport syndrome

  2013cited by this paper
• Role of renin-angiotensin system in activation of macrophages by modified lipoproteins.

  2013cited by this paper
• Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative

  2012cited by this paper
• Tubular toxicity of proteinuria

  2011cited by this paper
• Women and Alport syndrome

  2011cited by this paper
• Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease.

  2007cited by this paper
• How does proteinuria cause progressive renal damage?

  2006cited by this paper
• Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies.

  2004cited by this paper
• Alport's syndrome, Goodpasture's syndrome, and type IV collagen.

  2003cited by this paper
• X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study.

  2003cited by this paper
• Phenotypic and genotypic features of Alport syndrome in Chinese children

  2002influential reference
• Regulation of intrarenal angiotensin II in hypertension.

  2002cited by this paper
• Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling.

  2002influential reference
• Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system.

  2001cited by this paper
• REGULATION OF INTRARENAL ANGIOTENSIN II IN 2K1C RATS: 2C.5

  2000cited by this paper
• Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study.

  2000cited by this paper
• Alport syndromes: phenotypic heterogeneity of progressive hereditary nephritis

  2000cited by this paper
• X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males.

  2000cited by this paper
• Cardiac hypertrophy and cardiac renin–angiotensin system in Dahl rats on high salt intake

  2000cited by this paper
• RENAL PATHOLOGY AND ULTRASTRUCTURAL FINDINGS IN ALPORT'S SYNDROME

  2000cited by this paper
• Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages.

  1999cited by this paper
• X-linked Alport syndrome: an SSCP-based mutation survey over all 51 exons of the COL4A5 gene.

  1996cited by this paper
• Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats.

  1996influential reference
• Renal accumulation of circulating angiotensin II in angiotensin II-infused rats.

  1996influential reference
• Identification of a distinct type IV collagen alpha chain with restricted kidney distribution and assignment of its gene to the locus of X chromosome-linked Alport syndrome.

  1990cited by this paper
• Hereditary nephritis in children with and without characteristic glomerular basement membrane alterations.

  1988cited by this paper
• Genetics of classic Alport's syndrome.

  1988cited by this paper
• Release of renin and angiotensin II into plasma and lymph during hyperchloremia.

  1987cited by this paper
• Renal prognosis in women with hereditary nephritis.

  1985cited by this paper
• Kinetics of the human renin and human substrate reaction.

  1971cited by this paper

• No citing papers are available for this paper.